Key result
In high-risk patients with severe aortic stenosis undergoing TAVI, there was no significant difference in 12-month all-cause mortality between women and men.
Why the study?
Does gender affect clinical outcomes and quality of life in high-risk patients with severe aortic stenosis undergoing TAVI?
Observational (n=101)
No
Does gender affect clinical outcomes and quality of life in high-risk patients with severe aortic stenosis undergoing TAVI?
Answers are grounded in this paper and cite their sources.
TAVI is an effective and safe treatment in high-risk patients with severe aortic stenosis, with similar 30-day and 12-month mortality and quality of life improvements regardless of gender.
INTRODUCTION: There are inconsistent data on the sex-related differences in clinical outcomes and quality of life (QoL) after transcatheter aortic valve implantation (TAVI). AIM: We sought to investigate sex-related differences in procedural, clinical and QoL outcomes of TAVI. MATERIAL AND METHODS: A total of 101 consecutive patients undergoing TAVI were enrolled. Patients were stratified by gender. Baseline characteristics, procedural and long-term clinical outcomes as well as frailty and QoL indices (EQ-5D-3L questionnaire) were compared between women and men. RESULTS: Women represented 60.4% of the study population. Periprocedural risk measured with the Logistic EuroSCORE and STS scale was similar for women and men. There were no differences in 30-day or 12-month all-cause mortality between groups (women vs. men: 9.8% vs. 12.5%; age-adjusted odds ratio (OR) (95% CI): 1.38 (0.39-4.94); 13.1% vs. 25.0%; age-adjusted OR (95% CI): 2.51 (0.87-7.25)). Men were at higher risk of new onset atrial fibrillation at follow-up (1.6% vs. 17.5%; age-adjusted OR (95% CI): 14.61 (1.68-127.37)). In multivariable Cox regression analysis, a history of stroke/transient ischemic attack (TIA) (hazard ratio (HR)) (95% CI): 3.93 (1.39-11.07) and blood transfusion (HR (95% CI): 2.84 (1.06-7.63)) were identified as independent factors affecting 12-month mortality. No differences in QoL parameters were noted. CONCLUSIONS: The TAVI can be considered as an effective and safe treatment in high-risk patients with severe aortic stenosis, regardless of gender.
No takes yet. Share an insight, caveat, or question.
Bagieński et al. (2017) conducted an observational in Severe aortic stenosis (n=101). Female sex vs. Male sex was evaluated on 12-month all-cause mortality (OR 2.51, 95% CI 0.87-7.25, p=0.13). In high-risk patients with severe aortic stenosis undergoing TAVI, there was no significant difference in 12-month all-cause mortality between women and men.
Synapse has enriched 10 related papers. Consider them for comparative context: